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Scope: Insulin resistance (IR) and inflammation are hallmarks of type 2 diabetes (T2D). The nod-like receptor pyrin
domain containing-3 (NLRP3) inflammasome is a metabolic sensor activated by saturated fatty acids (SFA) initiating IL-
1𝜷 inflammation and IR. Interactions between SFA intake and NLRP3-related genetic variants may alter T2D risk factors.
Methods: Meta-analyses of six Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (n= 19 005)
tested interactions between SFA and NLRP3-related single-nucleotide polymorphisms (SNPs) and modulation of fasting
insulin, fasting glucose, and homeostasis model assessment of insulin resistance.
Results: SFA interacted with rs12143966, wherein each 1% increase in SFA intake increased insulin by 0.0063 IU mL−1
(SE ± 0.002, p = 0.001) per each major (G) allele copy. rs4925663, interacted with SFA (𝜷 ± SE = −0.0058 ± 0.002, p =
0.004) to increase insulin by 0.0058 IU mL−1, per additional copy of the major (C) allele. Both associations are close to
the significance threshold (p < 0.0001). rs4925663 causes a missense mutation affecting NLRP3 expression.
Conclusion: Two NLRP3-related SNPs showed potential interaction with SFA to modulate fasting insulin. Greater dietary
SFA intake accentuates T2D risk, which, subject to functional validation, may be further elaborated depending on NLRP3-
related genetic variants.
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1. Introduction
The rising prevalence of type 2 diabetes (T2D) has become a
worldwide public health concern.[1] The increase in T2D may be
attributable to recent changes in lifestyle including the adoption
of Western style diets high in saturated fats. Chronic low grade
inflammation has been widely implicated in the progression of
T2D risk factors such as hyperglycemia, hyperinsulinemia, and
insulin resistance (IR).[2–6] Immune cells such as macrophages
induce inflammation by recognizing a wide variety of pathogen
or damage-associated molecular patterns (P/DAMPS) via innate
immune sensors, toll-like receptors (TLR) or nod-like receptors
(NLR).[7] Saturated fatty acids (SFA) and their metabolites and ce-
ramides and diacylglycerol can activate TLRs andNLRs, initiating
a pro-inflammatory response.[2,8–12] Dietary saturated fats induce
a pro-inflammatory response concurrent with IR in humans and
hence play a key role in the pathogenesis of T2D.[13–16]
Recent identification of the nod-like receptor pyrin domain
containing-3 (NLRP3) inflammasome has established a mech-
anistic link between SFA and inflammation. The NLRP3 in-
flammasome is an important multi-protein complex that func-
tions as a metabolic stress sensor to initiate IL-1𝛽-mediated
inflammation.[17–20] Several studies using genetically modified
mouse models which lack components of the NLRP3 in-
flammasome (NLRP3, caspase-1, apoptosis-associated speck-like
protein containing a CARD, IL-1RI) provide mechanistic evi-
dence that NLRP3 inflammasome activation induces metabolic
inflammation and IR.[18–22] Results from the recent CAN-
TOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes
Study) trial showed that inhibitingNLRP3/IL-1𝛽 with therapeutic
antibody canakinumab significantly reduced inflammation and
cardiovascular events in patients with cardiovascular disease risk,
40% of which had diabetes.[23] In obese humans with T2D, caloric
restriction and exercise-mediated weight loss reduces NLRP3 in-
flammasome expression in adipose tissue and improves insulin
sensitivity.[18] In myeloid cells from T2D patients, NLRP3 inflam-
masome expression and IL-1𝛽 secretion was upregulated at base-
line. However, following 2 weeks of anti-diabeticmedicationmet-
formin, IL-1𝛽 production was reduced.[24] Importantly, SFAs act
as a NLRP3 trigger, priming and activating IL-1𝛽 leading to IR,
whereas unsaturated fatty acids do not.[19,25–27] Hence, the role of
dietary fat in modulating NLRP3 activity is of current interest for
T2D etiology.
While prospective evidence in humans strongly supports the
negative effects of SFA on inflammation and IR,[28–30] little is
known regarding NLRP3-related genetic variants and their inter-
action with an individual’s dietary and metabolic exposure and
response to SFA. Identifying inflammatory gene–nutrient inter-
actions may facilitate identification of individuals at high T2D
risk. Eventually, this may lead to applying targeted dietary rec-
ommendations to individuals who will respond most effectively
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Table 1. Description of six participating cohorts from the CHARGE Consortium (n = 19005).
Abbreviation Reference Region Sample
size
Age [years] Sex %
female
Cohort
Netherlands Epidemiology of Obesity Study NEO [65] Northern Europe 5071 55.8 ± 5.9 53.1
Cardiovascular Health Study CHS [66] United States 2746 72.3 ± 5.4 62.2
Cardiovascular Risk in Young Finns Study YFS [67] Northern Europe 1651 37.8 ± 3.9 55.7
Framingham Heart Study FHS [68] United States 5786 45.9 ± 11.5 54.7
Rotterdam Study I RS [69] Northern Europe 2507 69.5 ± 9.3 58.7
The Hellenic Study of Interactions between SNPs and
Eating in Atherosclerosis susceptibility
THISEAS [70] Greece 1244 58.0 ± 14.3 45.3
to dietary intervention.[31] The Genetics of Lipid Lowering Drugs
and Diet Network (GOLDN) study demonstrated important in-
teractions between IL-1𝛽 genetic variants and polyunsaturated
fats to decrease the risk of metabolic syndrome.[32] Complement
component 3 (C3) is an innate immune biomarker with dis-
tinct sensitivity to SFA. High dietary SFA intake further accen-
tuates the inflammatory impact of both circulating C3 and C3
genotype to augment IR.[33,34] Additionally, the combination of
IL-6, lymphotoxin-𝛼, and tumor necrosis factor-𝛼 inflammatory
risk genotypes interact with plasma fatty acid status to increase
metabolic syndrome risk.[35] Polymorphisms in the NLRP3 gene
have shown associations with T2D;[36–41] however, the role of diet
in these associations has not yet been investigated.
Based on the existing evidence, our hypothesis is that alter-
ing dietary SFA intake may modulate T2D risk through inter-
actions with NLRP3 inflammasome–related genetic variants. To
address this premise, we examined 489 SNPs within 12 candi-
date genes related to the NLRP3 inflammasome, for interactions
with dietary SFA intake, and quantified the extent to which these
interactions can modify glycemic outcomes. We performed in-
teraction analyses in 19 005 individuals from six independent
U.S. and European cohorts participating in the Cohorts for Heart




The present study was a collaboration of investigators from
U.S. and European cohort studies participating in the Nutri-
tion Working Group and Diabetes-Glycemia Working Group of
the CHARGE consortium. Contributing cohorts included the
Netherlands Epidemiology of Obesity study (NEO), Cardiovas-
cular Health Study (CHS), Cardiovascular Risk in Young Finns
Study (YFS), Framingham Heart Study (FHS), Rotterdam Study
(RS), and The Hellenic Study of Interactions between SNPs and
Eating in Atherosclerosis Susceptibility (THISEAS). Each of the
six contributing cohorts executed analyses locally according to
a pre-specified analysis plan and shared summary statistics for
meta-analyses. The six cohorts, providing results from up to
19 005 adults per analysis, are described in Table 1. This anal-
ysis was restricted to White participants, and free from preva-
lent diabetes mellitus (as defined by self-reported diabetes, fast-
ing glucose >7 mmol L−1, or use of diabetic medication). De-
tails on the design of each study are described in Section S1,
Supporting Information. All studies were conducted in accor-
dance to theHelsinki Declaration of 1975 as revised in 1983. Each
participating study had local institutional or national review
board approval, and written informed consent was obtained from
all participants.
2.2. Dietary Assessment and Body Mass Index
Habitual dietary intake data were collected from validated food
frequency questionnaires (Table S1, Supporting Information).
The type of food-frequency questionnaire used in each cohort
differed slightly to capture the dietary habits of the population
of interest. The current analysis focused on SFA intake as a per-
centage of total energy intake (%SFA). Body mass index (BMI)
was calculated from measured weight (kg) and height (m)2.
2.3. Genotyping, Fasting Glucose and Insulin Quantification, and
Homeostasis Model Assessment of Insulin Resistance
Calculations
Cohort-specific methods for genotyping and fasting glucose and
insulin quantification are described in Table S2, Supporting In-
formation. Fasting glucose and insulin were quantified by en-
zymatic methods and radioimmunoassay, respectively. Home-
ostasis Model Assessment of Insulin Resistance (HOMA-IR)
was calculated as fasting insulin (µU mL−1) × fasting glucose
(mmol L−1)/22.5. The 489 SNPs used in the present analysis were
selected using 1000 genomes based on their location within or
in surrounding regulatory regions of 12 candidate genes associ-
ated with the NLRP3 inflammasome (NLRP3, IL-1RI, IL-18RI,
IL-1𝛼, IL-1𝛽, IL-1RN, MYD88, nuclear factor 𝜅 B [NF𝜅B], TLR4,
Caspase-1, IL-18, PYCARD) listed in Table S3, Supporting Infor-
mation. SNPs with a minor allele frequency (MAF) of >15% and
a low level of linkage disequilibrium (LD r2 <0.8) were chosen
for analysis.
2.4. Statistical Analysis
Glucose was analyzed without transformation and insulin and
HOMA-IR were natural log (ln) transformed before analysis.
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Coefficients from regression analyses are presented for
(ln)insulin and (ln)HOMA-IR. For descriptive purposes, cohort
mean insulin and HOMA-IR concentrations were presented as
geometric means with 95% confidence intervals (C.I.).
2.5. Cohort-Specific Analysis
Each cohort performed a linear regression model to examine the
interaction between dietary SFA and candidate SNPs for three
metabolic traits (fasting glucose, fasting insulin, and HOMA-IR)
as outcomes. For interaction analyses, “dietary SFA” refers to
energy intake from SFA as percentage of total energy as a con-
tinuous variable. Each cohort provided 𝛽-coefficients, SEs, and
p-values for the following linear regression models: 1) interac-
tions between %SFA and 489 SNPs for fasting glucose concen-
trations, 2) interactions between %SFA and 489 SNPs for fasting
insulin concentrations, and 3) interactions between %SFA and
489 SNPs for HOMA-IR concentrations. Age, sex, BMI, total en-
ergy intake (kcal per day), and population specific variables (field
center, principle component analysis) were included in each lin-
ear regression model as covariates, and a random effect was in-
cluded to account for family structure when appropriate. Indi-
viduals were excluded from this study for the following reasons;
missing data on genotype, dietary assessment and/or outcome
measures, <18 years of age, diagnosed diabetes, pregnancy, or
non-European ancestry.
2.6. Meta-Analysis
Summary statistics from each cohort were combined using in-
verse variance weighted fixed effects meta-analysis with METAL
software to analyze main effects (SNP and SFA) and interactions
(SNP × SFA). For each SNP, an overall z-statistic and p-value
were calculated. Heterogeneity across studies was tested by us-
ing Cochran’s Q statistic and quantified by the I2 statistic.[42] All
interaction analyses withmoderate heterogeneity (I2 >30%) were
further assessed for potential sources of heterogeneity by meta-
regression analysis. Meta-regression analysis was conducted us-
ing the metafor package in R 3.21 (http://www.R-project.org/).
Each cohort had a number of missing SNPs from the list of 489
SNPs; therefore, a total of 401 SNPs with complete genotypic
counts were available for meta-analyses. Bonferroni correction
was set at p < 0.0001 (p = 0.05/401). SNPs of interest were in-
vestigated for functionality using publically available annotation
resources.[43,44]
3. Results
3.1. Participating CHARGE Cohorts Demonstrate a
Heterogeneous Population
A total of 19 005 non-diabetic participants from six US and Eu-
ropean cohorts were included in this analysis (Table 1). Partici-
pants were aged between 38 and 72 years, and there was a higher
percentage of females within each cohort, with the exception of
THISEAS. General characteristics of participants in each cohort
are reported in Table 2. Mean BMI exceeded 25 kg m−2 for all co-
horts. Total energy intake was variable, ranging from 1641 kcal
per day in the THISEAS study to 2383 kcal per day in the YFS.
The Dutch cohorts, RS and NEO study, had the highest total fat
and saturated fat intakes, with up to 36% of energy intake from
fat.
3.2. Meta-Analysis of 19 005 Subjects from Six Cohorts Identifies
NLRP3 Variants That Interact with Dietary SFA Intake to
Modulate Fasting Insulin and HOMA-IR
Meta-analyzed estimates of the interactions between dietary SFA
intake and selected SNPs on fasting insulin are presented in
Table 3. We observed potentially relevant interactions between
SFA and two SNPs with respect to fasting insulin concentrations;
these SNPs were genotyped in four out of six cohorts (Figure 1).
The interactions did not attain, but were close to, the pre-specified
Bonferroni-corrected significance level of p < 0.0001. The
Table 2. Dietary and metabolic characteristics of six U.S. and European cohort studies.
n NEO CHS YFS FHS RS THISEAS
5071 2746 1651 5786 2507 1244
BMI [kg m−2] 29.62 ± 4.65 26.01 ± 4.31 25.71 ± 4.47 26.68 ± 5.0 26.3 ± 3.7 27.91 ± 4.56
Total energy [kcal day−1] 2284 ± 706 2017.18 ± 647.51 2383.25 ± 769.21 1985.0 ± 663.5 1973 ± 503 1641 ± 708.00
Total fat [kcal day−1] 799 ± 317 662.67 ± 277.53 784.69 ± 292.71 622.8 ± 256.2 725.2 ± 245.6 582.81 ± 267.88
Total fat [% energy] 34.48 ± 5.62 32.21 ± 6.0 32.81 ± 4.81 31.25 ± 6.6 36.4 ± 6.2 35.78 ± 6.04
Saturated fat [kcal day−1] 289.05 ± 127.8 212.28 ± 95.46 282.09 ± 117.07 219.38 ± 98.2 287.3 ± 106 191.24 ± 104.40
Saturated fat [% energy] 12.43 ± 2.833 10.28 ± 2.23 11.74 ± 2.34 10.99 ± 3.0 14.4 ± 3.2 11.62 ± 3.10
Fasting glucose [mmol L−1] 5.47 ± 0.54 5.53 ± 0.52 5.26 ± 0.47 5.19 ± 0.5 5.5 ± 0.54 5.28 ± 0.63
Fasting insulin [uIU mL−1] 11.76 ± 7.58 13.49 ± 7.03 8.29 ± 6.28 4.95 ± 2.7 11.1 ± 8.3 8.83 ± 3.79
HOMA-IR 2.92 ± 2.04 3.37 ± 1.95 1.98 ± 1.61 1.17 ± 0.7 2.6 ± 1.6 2.08 ± 0.95
BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; NEO, The Netherlands Epidemiology of Obesity study; CHS, Cardiovascular Health
Study; YFS, Young Finns Study; FHS, FraminghamHeart Study; RS, Rotterdam Study I; THISEAS, The Hellenic study of Interactions between Single nucleotide polymorphisms
and Eating in Atherosclerosis Susceptibility.
All values are mean ± standard deviation (95% C.I.). Insulin was analyzed on the natural log scale and back-transformed to the geometric scale for presentation.
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Table 3.Meta-analyzed interactions between dietary saturated fatty acids (% total energy) and SNPs related to the NLRP3 inflammasome which impact
fasting insulin in six cohorts (CHS, YFS, FHS, NEO, RS, THISEAS). Nominally significant SNPs (p < 0.05) are presented.
SNP Nearest gene Chr Alleles major/minor MAF Regression coefficient for interaction between
SFA x SNP for fasting insulin [uIU mL−1]
𝛽 SE p-Value I2
NLRP3 related SNP
rs12143966 NLRP3 1 G/A 0.38 −0.0063 0.002 0.0019 0
rs4925663 OR2B11 1 C/T 0.40 −0.0058 0.002 0.0048 29.3
rs10737805 NLRP3 1 G/A 0.24 0.0068 0.0026 0.0088 13.5
rs12239046 NLRP3 1 C/T 0.41 0.0052 0.002 0.0114 0
rs4925546 NLRP3 1 G/A 0.37 0.005 0.002 0.0141 0
rs1539019 NLRP3 1 C/A 0.35 0.0052 0.0021 0.0145 0
rs3771158 IL-18RI 2 A/G 0.19 0.006 0.0025 0.0171 0
rs11687768 IL-18RI 2 A/G 0.19 0.006 0.0025 0.0204 0
rs10202813 IL-18RI 2 G/T 0.19 −0.006 0.0025 0.0210 0
rs10197310 IL-18RI 2 T/A 0.19 −0.006 0.0025 0.0211 0
rs569965 TLR4 9 G/C 0.38 0.004 0.0018 0.0214 0
rs7744 MyD88 3 A/G 0.14 −0.006 0.0029 0.0294 0
rs17419611 TLR4 9 G/T 0.08 0.0059 0.0027 0.0324 43.8
rs488992 Caspase 1 11 G/A 0.08 0.0065 0.0032 0.0431 0
rs2386549 NLRP3 1 C/G 0.10 −0.0099 0.005 0.0476 0
SNP, single nucleotide polymorphism; Chr, chromosome; MAF, minor allele frequency; 𝛽, regression coefficient for interaction between dietary saturated fats (% total energy)
× SNP for fasting insulin [uIU mL−1], adjusted for age, sex, BMI, total energy intake, and field center; I2, Cochran’s Q statistic.
p-Value adjusted for multiple comparisons with Bonferroni Correction p < 0.0001.
Figure 1. Forest plots of the interactions between rs12143966 and rs4925663 with dietary SFA intake for fasting insulin. For each cohort, linear regression
was used to examine the interactions of SFA intake (% energy) with each SNP for fasting insulin [uIU mL−1]. Meta-analysis was performed with the use
of inverse-variance-weighted fixed-effects models. Regression coefficients and 95% C.I. are represented by a filled square and horizontal line for each
cohort and overall (summary). CHS, Cardiovascular Health Study; FHS, Framingham Heart Study; RS, Rotterdam Study I; YFS, Young Finns Study.
intronic variant (rs12143966), located within theNLRP3 gene, in-
teracted with SFA intake (𝛽 ± SE = −0.0063 ± 0.002, p = 0.001).
This can be quantified by each 1% increase in SFA intake, in-
creased fasting insulin by 0.0063 uIU mL−1, per each additional
copy of the major (G) allele (MAF = 0.38). A second missense
variant rs4925663, located in the olfactory receptor family 2, sub-
family B member 11 (OR2B11) gene (Olfactory Receptor Family
2, Subfamily Bmember 11), showed a significant interactionwith
SFA, (𝛽 ± SE = −0.0058 ± 0.002, p = 0.004), such that a 0.0058
uIUmL−1 increase in fasting insulin was associated with each ad-
ditional 1% SFA intake, per each additional copy of the major (C)
allele (MAF = 0.4). These SNPs are located in close proximity on
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Table 4.Meta-analyzed interactions between dietary saturated fatty acids (% total energy) and SNPs related to the NLRP3 inflammasome which impact
HOMA-IR in 6 cohorts (CHS, YFS, FHS, NEO, RS, THISEAS). Nominally significant SNPs (p < 0.05) are presented.
SNP Nearest gene Chr Alleles major/minor MAF Regression coefficient for interaction between
SFA x SNP for HOMA-IR
𝛽 SE p Value I2
NLRP3 related SNP
rs12143966 NLRP3 1 G/A 0.38 0.0065 0.002 0.0020 46.5
rs4925663 OR2B11 1 C/T 0.40 −0.0064 0.002 0.0031 39.4
rs10737805 NLRP3 1 G/A 0.24 0.0076 0.0028 0.0061 13.3
rs17419611 TLR4 9 G/T 0.08 0.007 0.0029 0.0165 41.6
rs3771158 IL-18RI 2 A/G 0.19 0.0064 0.0027 0.0177 0
rs11687768 IL-18RI 2 A/G 0.19 0.0062 0.0027 0.0212 0
rs10202813 IL-18RI 2 G/T 0.19 −0.0062 0.0027 0.0212 0
rs10197310 IL-18RI 2 T/A 0.19 −0.0062 0.0027 0.0213 0
rs1539019 NLRP3 1 C/A 0.35 0.0051 0.0023 0.0248 35.8
rs488992 Caspase 1 11 G/A 0.08 0.0072 0.0034 0.0356 0
rs12239046 NLRP3 1 C/T 0.41 0.0044 0.0022 0.0409 33.3
rs4925546 NLRP3 1 G/A 0.37 0.0043 0.0022 0.0477 31.2
SNP, single nucleotide polymorphism; Chr, chromosome; MAF, minor allele frequency; 𝛽, regression coefficient for interaction between dietary saturated fats (% total energy)
× SNP for HOMA-IR, adjusted for age, sex, BMI, total energy intake, and field center; I2, Cochran’s Q statistic.
p-Value adjusted for multiple comparisons with Bonferroni Correction p < 0.0001.
chromosome 1q44 position, yet are not in linkage disequilibrium
(LD r2 0.628). We also observed weaker yet noteworthy interac-
tions between other NLRP3-, IL-18-, and TLR4-related SNPs and
dietary SFA intake to modulate fasting insulin concentrations.
Table 4 presents the SNP and SFA interactions for HOMA-
IR. These findings were relatively consistent with the fasting in-
sulin interactions; rs12143966NLRP3 (𝛽 ± SE=−0.0065± 0.002,
p = 0.002482); rs4925663 OR2B11 (𝛽 ± SE = −0.0064 ± 0.002,
p = 0.003099). However, these interactions did not reach statis-
tical significance for HOMA-IR. Furthermore the statistical het-
erogeneity of the meta-analysis between studies were moderately
high for both the rs12143966 variant (I2 = 46.5) and the rs4925663
variant (I2 = 39.4) suggesting that factors in addition to dietary
SFA and genotype are contributing to the variability in HOMA-
IR. Putative interactions between SFA and genotype for fasting
glucose did not reach significance (Table S4, Supporting Infor-
mation).
4. Discussion
The role of the NLRP3 inflammasome and IL-1𝛽 inflammation
in IR and T2D risk has gained much attention, with SFA central
to its mechanism. This is the first study to investigate the interac-
tion between NLRP3 variants and dietary SFA intake on T2D risk
factors. Meta-analysis of summary results obtained from 19 005
subjects from the CHARGE consortium demonstrates nominally
significant interactions between SFA intake and the NLRP3 vari-
ant rs12143966 and the OR2B11 rs4925663 variant, to modulate
fasting insulin levels. Individuals with one or two copies of the
major allele for these variants have greater fasting insulin levels
with higher SFA intake and may therefore benefit from reduc-
ing dietary SFA. As the major allele for both SNPs is present in
≈85% of the population, current recommendations for the gen-
eral population to reduce dietary SFA intake remain pertinent.
Both SNPs are closely located in the q44 region of chromosome
1, which has been described as a downstream regulatory region
for the NLRP3 gene in a study of Crohn’s disease.[45] To date, al-
though other NLRP3 SNPs have been associated with inflamma-
tory diseases,[36,37,45–49] these two variants have not been cited in
the literature as having any association with disease risk.
The rs12143966 variant lies near an intron within the NLRP3
gene, which may complicate the understanding of its functional-
ity. However, intronic variants may affect alternative splicing of
mRNA, have gene enhancing properties, or may be in high LD
with a functional variant. Further investigation of this SNP anno-
tation software revealed that although there was little information
available for the rs12143966 variant, it is in high LD with another
NLRP3-related SNP rs4925659 (r2 = 0.967). The rs4925659 vari-
ant is located within a strong enhancer region, with highly sig-
nificant expression quantitative trait loci (eQTL) hits for NLRP3
in human whole blood. We used the Haploreg webtool to inves-
tigate Chip-Seq signals from ENCODE to assess potential reg-
ulatory functions at the risk loci, and results suggest that the
rs4925659 variant falls within a genomic region to which tran-
scriptional cofactor B-cell lymphoma 3 (BCL3) and several other
related transcription factors bind. BCL3, involved in certain hu-
man B-cell leukemias, encodes a protein that functions as an
IĸB-like molecule, which attenuate NFĸB activation but is spe-
cific for the p50 subunit.[50] This is an interesting, yet unexplained
observation, as NF𝜅B is part of the NLRP3 inflammasome axis
and BCL3 binding may somehow be regulated by the presence
of the rs4925659 variant. The SNPs location within an enhancer
region that is specific to immune cells (B-cell leukocytes) re-
inforces support for its modulation of NLRP3 expression. Col-
lectively, these findings allow us to hypothesize that rs4925659,
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rather than rs12143966, is the variant of interest, interacting with
dietary SFA and responsible for modulating IR. However, this re-
mains a preliminary hypothesis and requires further functional
annotation.[51]
The OR2B11 rs4925663 SNP is a non-synonymous cod-
ing/missense variant, located within an olfactory receptor gene
associated with taste/olfaction. Missense variants alter the amino
acid sequence of a protein and result in a biological change
that is potentially deleterious. According to National Center for
Biotechnology Information dbSNP database, the ancestral allele
is “C” and the only variant allele reported there is “T.” Interest-
ingly, there are differences in major and minor alleles by ances-
try. For example, while the frequency of the T allele in HapMap
CEU (Northern Europeans) is 0.42, the frequency for HapMap
HCB (Han Chinese in Beijing) is 0.29 and in HapMap-YRI (Sub-
Saharan Africans in Yoruba) is 0.7. In the last case, the ma-
jor and minor alleles are reversed compared to the other an-
cestries. Haploreg shows eQTL hits for NLRP3 in blood and
liver tissues, adding strength to our hypothesis that these SNPs
may be sharing a regulatory element affecting expression of the
NLRP3 gene. The olfactory system is an emerging process that
may interact with the endocrine system to impact metabolic
health.[52,53] Olfactory inputs help coordinate food selection and
hormonal responses to impact energy homeostasis, adiposity,
and insulin resistance.[53] Conditional ablation of the insulin-like
growth factor-1 receptor in olfactory sensory neurons enhance ol-
factory performance in mice and leads to increased adiposity and
insulin resistance unraveling a new bidirectional function for the
olfactory system in controlling energy homeostasis in response
to sensory and hormonal signals.[53] Variants on olfaction genes
can also influence the innate immune response and are linked to
disease.[54] Large scale genome wide association studies reported
amissense mutation in tripartite motif 5 (TRIM5) which was sig-
nificantly associated with coronary artery disease (p= 2.1× 10−12,
OR 1.09 (C.I. 1.06, 1.11).[54] This variant interacted with eQTLs in
the promoters/enhancers of olfactory genes OR52S1, OR52B6,
and TRIM6 suggesting these genes enhance the expression of
TRIM5.[54] TRIM5 promotes Interferon 𝛾 as part of the innate
immune system.[54,55] Therefore, it is plausible that an olfactory
sensor variant may have functional consequences for insulin reg-
ulation. It is well recognized that variants in taste receptors can
influence glucose metabolism[56–60] and that taste receptors may
influence an individual’s preference for fat intake.[59–64] While
the full impact of olfaction gene variants on metabolism and
innate immune function remain to be defined, preliminary in-
sight would suggest possible biological interactions with habitual
diet to impact risk of T2D.
We acknowledge that these interactions did not meet the
highly stringent Bonferroni-corrected cut-off point for statistical
significance. Aside from the possibility that there is no real in-
teraction between SFA and these loci, the null results could still
reflect insufficient statistical power or misclassification in the
quantification of SFA intake. False negative results remain a chal-
lenge for this type of analysis, as we may be missing some true
gene–nutrient interactions. Furthermore, this was a candidate
gene study of 489 SNPs related to the NLRP3 inflammasome,
and while this analysis provided a novel hypothesis, we may be
missing some key SFA interactions with other inflammatory or
indeed non-inflammatory variants.
To conclude, this gene–nutrient interaction analysis identified
several NLRP3 inflammasome–related SNPs that interact with
SFA intake to modulate glycemic measures. These results sup-
port the growing evidence for the role of NLRP3 in the progres-
sion of T2D risk factors. While intriguing, results need to be in-
terpreted with caution and validated in other studies such as UK-
Biobank before disentangling themechanism by which genotype
influences phenotype. Nonetheless, this research provides inter-
esting observations for T2D biology, particularly with regards to
the olfactory receptor variant interactingwith dietary SFA tomod-
ulate insulin levels, and can inform future experimental studies.
Understanding how a modifiable dietary factor such as SFA in-
take interacts with inflammatory genes to alter measures of IR
may help identify at-risk individuals who can benefit from lower-
ing SFA intake to reduce their T2D risk. Recent evidence shows
that individuals are more likely to comply with personalized di-
etary advice over generic nutritional advice.[65] These nutrient-
sensitive genotypes offer potential for a “personalized nutrition”
approach to dietary advice.
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